Fierce Biotech digs into side effects: diarrhea reached 32.7% on retatrutide versus 26.4% on Ozempic, while constipation was lower. Lilly plans to file with the FDA in early 2027.
Recap by typeshit. Full story at Fierce Biotech.
Researchers compared short-term glycemic response to tirzepatide in type 2 diabetes patients based on whether they had used incretin drugs before.
Part of his GLP-1 series, Krittanawong discusses whether the drugs could help MASLD and MASH, and how visceral fat can drive metabolic problems unseen.
16:32
Dr. Kevin Joseph, DO, who treats liver disease daily, shares his views on peptides. The claims are his own, not established treatment guidance.
Dr. Jonathan Stegall shares the data: about 13 in 100 GLP-1 users with stage 1 to 3 colorectal cancer saw it spread, versus about 22 in 100 on another diabetes drug.
Health NZ is warning that many peptides people inject are unapproved and unregulated, even as demand for the kits keeps growing.
IFF lays out five hydration need states for GLP-1 users, and Innova counts a 190% rise in launches carrying GLP-1-friendly claims.
Loading…